Clin Mol Hepatol.
2024 Jan;30(1):118-120. 10.3350/cmh.2023.0472.
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
- Affiliations
-
- 1Department of Gastroenterology and Hepatology, Tan Tock Seng Hospital, Singapore
- 2Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
- 3Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
- 4State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
- 5National Skin Centre and Skin Research Institute of Singapore (SRIS), Singapore
- KMID: 2549390
- DOI: http://doi.org/10.3350/cmh.2023.0472
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
- Waiting for the changes after the adoption of steatotic liver disease
- A new Korean nomenclature for steatotic liver disease: Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)
- Ursolic acid: A promising therapeutic agent for metabolic dysfunction-associated steatotic liver disease via inhibition of SPP1-induced Th17 cell differentiation: Editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”
- Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
